A new study offers hope for people with oral cavity cancer who struggle with anxiety and depression. Researchers tested two common medicines and found both helped ease psychological distress. Patients saw real improvements in their mood within just a few weeks.
Oral cavity cancer affects the mouth and throat. It can change how a person looks, speaks, and eats. These visible changes often lead to social stigma and withdrawal. Many patients feel intense anxiety and depression during treatment. This distress can make it harder to stick with treatment and can lower quality of life. Until now, there has not been a clear answer for which medication works best for these patients.
But here is the twist. Doctors often avoid strong psychiatric drugs in cancer patients due to side effects. This study compared two well-known options at low doses. Both are used for depression and sleep issues, but they work in different ways. The goal was to see which one helps oral cancer patients more safely.
Mirtazapine works like a key that unlocks two doors at once. It boosts serotonin and norepinephrine while blocking certain receptors that cause side effects. Olanzapine works more like a dimmer switch for several brain chemicals. It can calm anxiety but may cause weight gain and sleepiness. Both drugs affect appetite, which can be helpful for cancer patients who struggle to eat.
The study included 144 patients with oral cavity cancer. All had signs of psychological distress. They were split into two equal groups of 77 people each. One group took mirtazapine 15 mg at bedtime. The other took olanzapine 5 mg at bedtime. Doctors measured anxiety and depression using the Hospital Anxiety and Depression Scale at the start, then at two weeks and four weeks.
Both groups saw big improvements in their scores. Anxiety and depression dropped significantly in both groups. Mirtazapine led to a slightly greater reduction in symptoms compared to olanzapine. For anxiety, mirtazapine scores fell from 14.10 at admission to 10.28 by week four. Olanzapine scores dropped from 14.08 to 10.97. For depression, mirtazapine scores went from 14.07 to 10.24. Olanzapine scores fell from 14.01 to 10.98.
Both medicines helped, but mirtazapine showed a slight edge.
The overall effect of the drugs was statistically significant. However, there was no significant interaction between the drug type and time. This means both drugs worked steadily over the four weeks, but one did not work faster than the other. The results suggest that either drug could be a good option for oral cancer patients with distress.
An independent expert not involved in the study noted that these findings align with earlier research on depression in cancer patients. The expert added that choosing between the two drugs may depend on individual side effect profiles and patient preferences. For example, patients who need help with sleep and appetite might benefit more from mirtazapine.
What does this mean for you or a loved one with oral cancer? If you are struggling with anxiety or depression, talk to your oncology team. Ask whether a low-dose antidepressant could be part of your care plan. Do not start or stop any medication without medical guidance. These drugs require a prescription and close monitoring.
This study has some limits. It was a single-center study with a relatively small number of patients. The follow-up period was only four weeks, so long-term effects are unknown. The study focused on oral cavity cancer, so results may not apply to other cancer types.
Researchers plan to conduct larger trials with longer follow-up. They also want to test these drugs in other cancer populations. For now, this study gives doctors a clearer path to help patients with oral cancer who face psychological distress. The goal is to improve quality of life and treatment adherence while keeping side effects low.